E. McKone (Dublin 4, Ireland), F. Vermeulen (Leuven, Belgium)
Lymphocyte responses to Mycobacterium tuberculosis and Mycobacterium bovis are similar between BCG-vaccinated patients with cystic fibrosis and healthy controls
R. Mauch (Campinas (SP), Brazil), P. Alves (Campinas (SP), Brazil), C. Levy (Campinas (SP), Brazil), J. Ribeiro (Campinas (SP), Brazil), A. Ribeiro (Campinas (SP), Brazil), N. Høiby (Copenhagen, Denmark), M. Nolasco Da Silva (Campinas (SP), Brazil)
|   |
Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients
R. Kos (Amsterdam, Netherlands), P. Brinkman (Amsterdam, Netherlands), A. Neerincx (Amsterdam, Netherlands), T. Paff (Amsterdam, Netherlands), M. Gerritsen (Amsterdam, Netherlands), A. Lammers (Amsterdam, Netherlands), A. Kraneveld (Utrecht, Netherlands), H. Heijerman (Utrecht, Netherlands), J. Davies (London, United Kingdom), H. Janssens (Rotterdam, Netherlands), C. Majoor (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands), P. Sterk (Amsterdam, Netherlands), E. Haarman (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands)
| |
Comparative in vitro activity of fluoroquinolones against P. aeruginosa isolated from Greek CF patients
D. Ioannidou (Thessaloniki, Greece), A. Tychala (Thessaloniki, Greece), E. Faniadou (Thessaloniki, Greece), C. Michailidou (Thessaloniki, Greece), K. Manika (Thessaloniki, Greece), E. Hatziagorou (Thessaloniki, Greece), I. Kioumis (Thessaloniki, Greece)
| |
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
D. Ademhan Tural (Ankara, Turkey), B. Ozsezen (Ankara, Turkey), B. Sunman (Ankara, Turkey), G. Hazirolan (Ankara, Turkey), N. Emiralioglu (Ankara, Turkey), E. Yalcin (Ankara, Turkey), D. Dogru (Ankara, Turkey), U. Ozcelik (Ankara, Turkey), N. Kiper (Ankara, Turkey)
| |
Myroides odorarus another one from the new emerging pathogens in cystic fibrosis – case report
G. Petrova (Sofia, Bulgaria), D. Miteva (Sofia, Bulgaria), T. Strateva (Sofia, Bulgaria)
| |
Changes in local and systemic inflammatory markers in cystic fibrosis patients chronically infected with Burkholderia cepacia complex
D. Pukhalskaya ( Moscow, Russian Federation), V. Shmarin ( Moscow, Russian Federation), S. Semykin ( Moscow, Russian Federation), L. Avakian ( Moscow, Russian Federation), N. Kashirskaya ( Moscow, Russian Federation), G. Shmarina ( Moscow, Russian Federation), V. Alioshkin ( Moscow, Russian Federation)
| |
A review of treatment regimens at first isolation of PA in a single cystic fibrosis center
H. Mursaloglu (Istanbul, Turkey), C. Akin (Istanbul, Turkey), C. Yilmaz (Istanbul, Turkey), P. Ergenekon (Istanbul, Turkey), Y. Gokdemir (Istanbul, Turkey), E. Erdem Eralp (Istanbul, Turkey), F. Karakoc (Istanbul, Turkey), A. Karahasan (Istanbul, Turkey), B. Karadag (Istanbul, Turkey)
| |
Usefulness of measurement of tobramycin levels in the era of once daily iv-treatment
F. Brinkmann (Bochum, Germany), A. Schlegtendal (Bochum, Germany), S. Dillenhoefer (Bochum, Germany), C. Koerner-Rettberg (Bochum, Germany)
| |
Predictors of eradication failure at first isolation of MRSA in cystic fibrosis patients
H. Mursaloglu (Istanbul, Turkey), C. Akin (Istanbul, Turkey), C. Yilmaz (Istanbul, Turkey), P. Ergenekon (Istanbul, Turkey), Y. Gokdemir (Istanbul, Turkey), E. Erdem Eralp (Istanbul, Turkey), F. Karakoc (Istanbul, Turkey), A. Karahasan (Istanbul, Turkey), B. Karadag (Istanbul, Turkey)
| |
Altered composition of Innate lymphoid cells in BAL and blood of adult patients with cystic fibrosis towards ILC1
H. Beckert (Essen, Germany), S. Plicht (Düsseldorf, Germany), S. Sutharsan (Essen, Germany), J. Harelimana (Düsseldorf, Germany), M. Jacobsen (Düsseldorf, Germany), C. Taube (Essen, Germany), N. Nausch (Düsseldorf, Germany)
| |
Use of BIOFIRE® Pneumonia Panel Plus on sputum from patients with Cystic fibrosis or PCD
P. Koliopoulos (Mainz, Germany), J. Jurak (Mainz, Germany), S. Schlotter (Mainz, Germany), O. Nitsche (Mainz, Germany), K. Bohn (Mainz, Germany), D. Schreiner (Mainz, Germany), S. Gehring (Mainz, Germany), K. Poplawska (Mainz, Germany)
| |
The efficacy and tolerability of inhaled hypertonic saline in children with cystic fibrosis
K. Skriabina (Dnipro, Ukraine), S. Ilchenko (Dnipro, Ukraine), A. Fialkovska (Dnipro, Ukraine)
| |
Clinical surveys with nebulised hypertonic saline (HS) in CF children
. Bernek (Starnberg, Germany), M. Ollmann-Selinger (Gräfelfing, Germany), R. Ledermüller (Starnberg, Germany)
| |
The Effects of Nebulizer Cleaning and Disinfection Training On The Knowledge Levels and Practises of the Caregivers of Patients with Cystic Fibrosis
C. Yegit (Istanbul, Turkey), P. Ergenekon (Istanbul, Turkey), H. Mursaloglu (Istanbul, Turkey), G. Tastan (Istanbul, Turkey), B. Suzer Uzunoglu (Istanbul, Turkey), Y. Gokdemir (Istanbul, Turkey), E. Erdem Eralp (Istanbul, Turkey), N. Duman (Istanbul, Turkey), A. Karahasan (Istanbul, Turkey), F. Karakoc (Istanbul, Turkey), B. Karadag (Istanbul, Turkey)
| |
Immunohistochemical evidence of increased neutrophil swarms in Cystic Fibrosis lung removed at transplantation
K. Jiwa (Newcastle-upon-Tyne, United Kingdom), C. Ward (Newcastle-upon-Tyne, United Kingdom), G. Parry (Newcastle-upon-Tyne, United Kingdom), M. Brodlie (Newcastle-upon-Tyne, United Kingdom), J. Lordan (Newcastle-upon-Tyne, United Kingdom), A. Fisher (Newcastle-upon-Tyne, United Kingdom), J. Garnett (Biberach an der Riss, Germany)
| |
Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis
G. Tetz (New York, United States of America), K. Kardava (Saint Petersburg, Russian Federation), T. Gembitskaya (Saint Petersburg, Russian Federation), M. Vecherkovskaya (Saint Petersburg, Russian Federation), V. Tetz (Saint Petersburg, Russian Federation)
| |